


## TC-G 24

Cat. No.:	HY-107529
CAS No.:	1257256-44-2
Molecular Formula:	C <sub>15</sub> H <sub>11</sub> ClN <sub>4</sub> O <sub>3</sub>
Molecular Weight:	330.73
Target:	GSK-3
Pathway:	PI3K/Akt/mTOR; Stem Cell/Wnt
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	TC-G 24 (Compound 24) is a potent, selective glycogen synthase kinase-3 $\beta$ (GSK-3 $\beta$ ) inhibitor with an IC <sub>50</sub> of 17.1 nM. TC-G 24 can cross the BBB and can be used for studying many diseases such as type 2 diabetes mellitus, stroke, Alzheimer, and other related diseases <sup>[1]</sup> .								
<b>IC<sub>50</sub> &amp; Target</b>	GSK-3 $\beta$ 17.1 nM (IC <sub>50</sub> )								
<b>In Vitro</b>	<p>TC-G 24 (Compound 24) binds to the ATP binding site of GSK-3<math>\beta</math><sup>[1]</sup>.</p> <p>TC-G 24 (1 <math>\mu</math>M, 4 h) blocks the FBW7<math>\alpha</math>-mediated degradation of TPP1 in human embryonic kidney (HEK) 293T cells<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Western Blot Analysis<sup>[2]</sup></p> <table border="1"> <tr> <td>Cell Line:</td> <td>293T cells</td> </tr> <tr> <td>Concentration:</td> <td>1 <math>\mu</math>M</td> </tr> <tr> <td>Incubation Time:</td> <td>4 h</td> </tr> <tr> <td>Result:</td> <td>Blocked the FBW7<math>\alpha</math>-mediated degradation of TPP1</td> </tr> </table>	Cell Line:	293T cells	Concentration:	1 $\mu$ M	Incubation Time:	4 h	Result:	Blocked the FBW7 $\alpha$ -mediated degradation of TPP1
Cell Line:	293T cells								
Concentration:	1 $\mu$ M								
Incubation Time:	4 h								
Result:	Blocked the FBW7 $\alpha$ -mediated degradation of TPP1								
<b>In Vivo</b>	<p>TC-G 24 (Compound 24) (0-15 mg/kg; i.p.; once) significantly raises liver glycogen content in a dose-dependent manner without obvious toxicity and can cross the BBB<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Six-week-old male C57BL/6N mice with weights averaging 22 g<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>1, 5, and 15 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection, once</td> </tr> <tr> <td>Result:</td> <td>Significantly raised liver glycogen content in a dose-dependent manner without obvious toxicity. Was detected in the brain at concentrations higher than in plasma for all three tested doses (38 <math>\pm</math> 6, 113 <math>\pm</math> 54 and 286 <math>\pm</math> 58 ng/g brain tissue at 1, 5 and 15 mg/kg,</td> </tr> </table>	Animal Model:	Six-week-old male C57BL/6N mice with weights averaging 22 g <sup>[1]</sup>	Dosage:	1, 5, and 15 mg/kg	Administration:	Intraperitoneal injection, once	Result:	Significantly raised liver glycogen content in a dose-dependent manner without obvious toxicity. Was detected in the brain at concentrations higher than in plasma for all three tested doses (38 $\pm$ 6, 113 $\pm$ 54 and 286 $\pm$ 58 ng/g brain tissue at 1, 5 and 15 mg/kg,
Animal Model:	Six-week-old male C57BL/6N mice with weights averaging 22 g <sup>[1]</sup>								
Dosage:	1, 5, and 15 mg/kg								
Administration:	Intraperitoneal injection, once								
Result:	Significantly raised liver glycogen content in a dose-dependent manner without obvious toxicity. Was detected in the brain at concentrations higher than in plasma for all three tested doses (38 $\pm$ 6, 113 $\pm$ 54 and 286 $\pm$ 58 ng/g brain tissue at 1, 5 and 15 mg/kg,								

---

respectively).

---

## REFERENCES

---

- [1]. Khanfar MA, et al. Discovery of novel GSK-3 $\beta$  inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening. J Med Chem. 2010 Dec 23;53(24):8534-45.
- [2]. Lihui Wang, et al. FBW7 Mediates Senescence and Pulmonary Fibrosis through Telomere Uncapping. Cell Metab. 2020 Nov 3;32(5):860-877.e9.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA